Needle-free drug delivery company Bioject Medical Technologies (OTC:BJCT) announced the departure of its president & CEO "for cost-cutting reasons" on the heels of major cuts to its workforce.
Ralph Makar, who took the corner office at Bioject four years ago, ceded his role to board member Mark Logomasini, who will serve as interim president & CEO, effective immediately.